FourThought Financial Partners LLC Acquires Shares of 362 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

FourThought Financial Partners LLC acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 362 shares of the company’s stock, valued at approximately $201,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. TCG Advisory Services LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $24,155,000. Sapient Capital LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $18,842,000. Axxcess Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $2,090,000. Malaga Cove Capital LLC increased its position in shares of IDEXX Laboratories by 36.7% during the fourth quarter. Malaga Cove Capital LLC now owns 928 shares of the company’s stock worth $515,000 after acquiring an additional 249 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its position in shares of IDEXX Laboratories by 58.1% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,621 shares of the company’s stock worth $900,000 after acquiring an additional 596 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on IDXX. The Goldman Sachs Group boosted their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Piper Sandler lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a report on Tuesday, January 30th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Thursday. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, Barclays decreased their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $580.88.

Insider Transactions at IDEXX Laboratories

In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the transaction, the chief executive officer now directly owns 79,247 shares in the company, valued at $45,377,624.67. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the completion of the sale, the chief executive officer now directly owns 79,247 shares in the company, valued at $45,377,624.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brian P. Mckeon sold 23,326 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the transaction, the chief financial officer now directly owns 29,718 shares in the company, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. Over the last three months, insiders sold 43,524 shares of company stock worth $24,871,960. Company insiders own 2.18% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX traded down $4.44 during midday trading on Monday, hitting $476.16. 100,774 shares of the company’s stock were exchanged, compared to its average volume of 440,513. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. The stock’s 50 day moving average price is $523.29 and its 200-day moving average price is $513.58. The firm has a market cap of $39.33 billion, a P/E ratio of 46.52, a PEG ratio of 3.78 and a beta of 1.27. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.20. The business had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the firm posted $2.05 earnings per share. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.05 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.